Loading...
Mortality from heart failure remains unacceptably high. Results from secondary prevention trials have suggested that omega-3 polyunsaturated fatty acids (PUFAs) might confer a 20% relative reduction in risk for death (JW Cardiol Nov 8 2006) in patients with coronary heart disease, apparently through anti-arrhythmic effects. No large-scale trials of PUFAs have been conducted in patients with heart failure.
In a trial from the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico (GISSI), sponsored by multiple industry partners, investigators randomized 6975 patients with symptomatic, chronic heart failure (NYHA classes II–IV) to receive placebo or an omega-3 PUFA supplement in addition to their other medications. Median fo…